“These data are consistent with the results from the PHOTON trial in diabetic macular edema, with both trials demonstrating a consistent safety profile with substantially fewer treatments than EYLEA.” “In the PULSAR trial, aflibercept 8 mg achieved impressive durability, while importantly maintaining visual acuity gains from year one through year two,” he said in the news release. Wykoff, MD, PhD, director of Research at Retina Consultants of Texas and a trial investigator, explained it was great to see aflibercept 8 mg deliver promising results. At the end of two years, 78% were eligible for ≥16-week dosing, with 53% eligible for ≥ 20-dosing week intervals.Ĭharles C. Of those assigned to ≥16-week dosing regimen at baseline, 70% maintained ≥ 16-week dosing intervals throughout the two-year study period.71% met the extension criteria for even longer dosing intervals, including 47% for ≥ 20-week intervals and 28% for 24-week intervals.78% maintained ≥ 12-week dosing intervals throughout the two-year study period, compared to 83% throughout the first year of study (48 weeks).88% were on a ≥ 12-week dosing interval at the end of two years.The company also noted in its release the longer-term data follow the positive two-year results for PHOTON with diabetic macular edema (DME), with PULSAR similarly demonstrating that the vast majority of aflibercept 8 mg patients with wAMD were able to maintain or further extend their dosing intervals.Īmong those who completed the two-year follow-up: today announced positive, two-year (96 weeks), topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related macular degeneration (wAMD).Īccording to a company news release, during the clinical trial, aflibercept 8 mg patients were initially randomly assigned to either 12- or 16-week dosing intervals (after three initial monthly doses) and were able to shorten or extend dosing intervals if pre-specified criteria were met.
0 kommentar(er)
